Drug Trial Radar · NCT06184659
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,800
Planned (sponsor's estimate)
Start
Jun 26, 2025
Primary completion
Jun 30, 2028
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Scandinavian Critical Care Trials GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.
Conditions
- Sepsis
- Septic Shock
Interventions
MeropenemDrug
For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
Piperacillin/TazobactamDrug
Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: Baseline to 30 days after enrollment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark · Recruiting
Rigshospitalet
Copenhagen, København Ø, Denmark · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.